Examining Bias in Studies of Statin Treatment and Survival in Patients With Cancer | Cardiology | JAMA Oncology | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
Meng  Y, Liao  YB, Xu  P, Wei  WR, Wang  J.  Statin use and mortality of patients with prostate cancer: a meta-analysis.  Onco Targets Ther. 2016;9:1689-1696.PubMedGoogle Scholar
Manthravadi  S, Shrestha  A, Madhusudhana  S.  Impact of statin use on cancer recurrence and mortality in breast cancer: a systematic review and meta-analysis.  Int J Cancer. 2016;139(6):1281-1288.PubMedGoogle ScholarCrossref
Gray  RT, Coleman  HG, Hughes  C, Murray  LJ, Cardwell  CR.  Statin use and survival in colorectal cancer: results from a population-based cohort study and an updated systematic review and meta-analysis.  Cancer Epidemiol. 2016;45:71-81.PubMedGoogle ScholarCrossref
Chou  R, Dana  T, Blazina  I, Daeges  M, Jeanne  TL.  Statins for prevention of cardiovascular disease in adults: evidence report and systematic review for the US Preventive Services Task Force.  JAMA. 2016;316(19):2008-2024.PubMedGoogle ScholarCrossref
Caporaso  NE.  Statins and cancer-related mortality—let’s work together.  N Engl J Med. 2012;367(19):1848-1850.PubMedGoogle ScholarCrossref
Spampanato  C, De Maria  S, Sarnataro  M,  et al.  Simvastatin inhibits cancer cell growth by inducing apoptosis correlated to activation of Bax and down-regulation of BCL-2 gene expression.  Int J Oncol. 2012;40(4):935-941.PubMedGoogle ScholarCrossref
Lévesque  LE, Hanley  JA, Kezouh  A, Suissa  S.  Problem of immortal time bias in cohort studies: example using statins for preventing progression of diabetes.  BMJ. 2010;340:b5087.PubMedGoogle ScholarCrossref
Danaei  G, Tavakkoli  M, Hernán  MA.  Bias in observational studies of prevalent users: lessons for comparative effectiveness research from a meta-analysis of statins.  Am J Epidemiol. 2012;175(4):250-262.PubMedGoogle ScholarCrossref
Warren  JL, Klabunde  CN, Schrag  D, Bach  PB, Riley  GF.  Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population.  Med Care. 2002;40(8)(suppl):IV-3-IV-18.PubMedGoogle Scholar
Black  L, Runken  MC, Eaddy  M, Shah  M.  Chronic disease prevalence and burden in elderly men: an analysis of Medicare medical claims data.  J Health Care Finance. 2007;33(4):68-78.PubMedGoogle Scholar
Herzog  CA, Muster  HA, Li  S, Collins  AJ.  Impact of congestive heart failure, chronic kidney disease, and anemia on survival in the Medicare population.  J Card Fail. 2004;10(6):467-472.PubMedGoogle ScholarCrossref
Sandgren  PE, Murray  AM, Herzog  CA,  et al.  Anemia and new-onset congestive heart failure in the general Medicare population.  J Card Fail. 2005;11(2):99-105.PubMedGoogle ScholarCrossref
Spettell  CM, Wall  TC, Allison  J,  et al.  Identifying physician-recognized depression from administrative data: consequences for quality measurement.  Health Serv Res. 2003;38(4):1081-1102.PubMedGoogle ScholarCrossref
CCW Task Order 10 Inter-Agency Panel working document and input from subject matter experts. https://ccwdata.org/cs/groups/public/documents/document/clin_cond_refer.pdf. Accessed August 15, 2016.
Hedley Dodd  A, Gleason  P. Using the MAX-NHANES Merged Data to Evaluate the Association of Obesity and Medicaid Costs [2013]. https://www.cms.gov/Research-Statistics-Data-and-Systems/Computer-Data-and-Systems/MedicaidDataSourcesGenInfo/Downloads/MAX_IB16_MAX_NHANES.PDF. Accessed August 15, 2016.
Klabunde  CN, Potosky  AL, Legler  JM, Warren  JL.  Development of a comorbidity index using physician claims data.  J Clin Epidemiol. 2000;53(12):1258-1267.PubMedGoogle ScholarCrossref
Hernán  MA, Sauer  BC, Hernández-Díaz  S, Platt  R, Shrier  I.  Specifying a target trial prevents immortal time bias and other self-inflicted injuries in observational analyses.  J Clin Epidemiol. 2016;79:70-75.PubMedGoogle ScholarCrossref
Thompson  WA  Jr.  On the treatment of grouped observations in life studies.  Biometrics. 1977;33(3):463-470.PubMedGoogle ScholarCrossref
Hernan  M, Robins  J.  Causal Inference. Boca Raton, FL: Chapman & Hall/CRC; 2017.
Luo  Y, She  DL, Xiong  H, Fu  SJ, Yang  L.  The prognostic effect of statin use on urologic cancers: an updated meta-analysis of 35 observational studies.  Medicine (Baltimore). 2015;94(36):e1523.PubMedGoogle ScholarCrossref
DerSimonian  R, Laird  N.  Meta-analysis in clinical trials.  Control Clin Trials. 1986;7(3):177-188.PubMedGoogle ScholarCrossref
Murtola  TJ, Visvanathan  K, Artama  M, Vainio  H, Pukkala  E.  Statin use and breast cancer survival: a nationwide cohort study from Finland.  PLoS One. 2014;9(10):e110231.PubMedGoogle ScholarCrossref
Katz  MS, Carroll  PR, Cowan  JE, Chan  JM, D’Amico  AV.  Association of statin and nonsteroidal anti-inflammatory drug use with prostate cancer outcomes: results from CaPSURE.  BJU Int. 2010;106(5):627-632.PubMedGoogle ScholarCrossref
Lakha  F, Theodoratou  E, Farrington  SM,  et al.  Statin use and association with colorectal cancer survival and risk: case control study with prescription data linkage.  BMC Cancer. 2012;12:487.PubMedGoogle ScholarCrossref
Geybels  MS, Wright  JL, Holt  SK, Kolb  S, Feng  Z, Stanford  JL.  Statin use in relation to prostate cancer outcomes in a population-based patient cohort study.  Prostate. 2013;73(11):1214-1222.PubMedGoogle ScholarCrossref
Desai  P, Lehman  A, Chlebowski  RT,  et al.  Statins and breast cancer stage and mortality in the Women’s Health Initiative.  Cancer Causes Control. 2015;26(4):529-539.PubMedGoogle ScholarCrossref
Brewer  TM, Masuda  H, Liu  DD,  et al.  Statin use in primary inflammatory breast cancer: a cohort study.  Br J Cancer. 2013;109(2):318-324.PubMedGoogle ScholarCrossref
Caon  J, Paquette  M, Hamm  J, Pickles  T.  Does statin or ASA affect survival when prostate cancer is treated with external beam radiation therapy?  Prostate Cancer. 2014;2014(4):184297.PubMedGoogle Scholar
Nielsen  SF, Nordestgaard  BG, Bojesen  SE.  Statin use and reduced cancer-related mortality.  N Engl J Med. 2012;367(19):1792-1802.PubMedGoogle ScholarCrossref
Siddiqui  AA, Nazario  H, Mahgoub  A, Patel  M, Cipher  D, Spechler  SJ.  For patients with colorectal cancer, the long-term use of statins is associated with better clinical outcomes.  Dig Dis Sci. 2009;54(6):1307-1311.PubMedGoogle ScholarCrossref
Shao  YY, Hsu  CH, Yeh  KH,  et al.  Statin use is associated with improved prognosis of colorectal cancer in Taiwan.  Clin Colorectal Cancer. 2015;14(3):177-184.e4.PubMedGoogle ScholarCrossref
da Silva  RD, Xylinas  E, Kluth  L,  et al.  Impact of statin use on oncologic outcomes in patients with urothelial carcinoma of the bladder treated with radical cystectomy.  J Urol. 2013;190(2):487-492.PubMedGoogle ScholarCrossref
Hoffmeister  M, Jansen  L, Rudolph  A,  et al.  Statin use and survival after colorectal cancer: the importance of comprehensive confounder adjustment.  J Natl Cancer Inst. 2015;107(6):djv045.PubMedGoogle ScholarCrossref
Chan  JM, Kenfield  SA, Paciorek  A, Platz  EA, Giovannucci  EL, Stampfer  MJ.  Postdiagnostic statin use and the risk of lethal prostate cancer in the health professionals follow-up study.  Cancer Epidemiol Biomarkers Prev. 2015;24(10):1638-1640.PubMedGoogle ScholarCrossref
Suissa  S, Dell’aniello  S, Vahey  S, Renoux  C.  Time-window bias in case-control studies: statins and lung cancer.  Epidemiology. 2011;22(2):228-231.PubMedGoogle ScholarCrossref
Hernández-Díaz  S.  Name of the bias and sex of the angels.  Epidemiology. 2011;22(2):232-233.PubMedGoogle ScholarCrossref
Hernán  MA, Robins  JM.  Using big data to emulate a target trial when a randomized trial is not available.  Am J Epidemiol. 2016;183(8):758-764.PubMedGoogle ScholarCrossref
Dale  KM, Coleman  CI, Henyan  NN, Kluger  J, White  CM.  Statins and cancer risk: a meta-analysis.  JAMA. 2006;295(1):74-80.PubMedGoogle ScholarCrossref
Emberson  JR, Kearney  PM, Blackwell  L,  et al; Cholesterol Treatment Trialists’ (CTT) Collaboration.  Lack of effect of lowering LDL cholesterol on cancer: meta-analysis of individual data from 175,000 people in 27 randomised trials of statin therapy.  PLoS One. 2012;7(1):e29849.PubMedGoogle ScholarCrossref
Original Investigation
January 2018

Examining Bias in Studies of Statin Treatment and Survival in Patients With Cancer

Author Affiliations
  • 1Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts
  • 2Institute of Health and Society, University of Oslo, Oslo, Norway
  • 3Primary Care Research Unit, Vårdcentralen Värmlands Nysäter, Värmland County, Sweden
  • 4Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, Massachusetts
  • 5Harvard-MIT Division of Health Science and Technology, Boston, Massachusetts
JAMA Oncol. 2018;4(1):63-70. doi:10.1001/jamaoncol.2017.2752
Key Points

Question  Does selection and immortal-time bias influence the findings in studies of use of statin therapy that report reduced early cancer-specific and all-cause mortality in patients with recently diagnosed prostate, breast, colorectal, or bladder cancer?

Findings  In patients with cancer identified through the SEER-Medicare database, the hazard ratios of mortality were 1 in comparisons between those who began statin therapy and those who did not. Strong, apparently beneficial effects of statin therapy use estimated by previous observational studies are likely owing to selection bias and immortal-time bias, biases that can be prevented with an appropriate study design.

Meaning  An explicit target trial emulation helps avoid misleading estimates and found no evidence that initiation of statin therapy improves 3-year survival in patients with cancer.


Importance  Patients with cancer who use statins appear to have a substantially better survival than nonusers in observational studies. However, this inverse association between statin use and mortality may be due to selection bias and immortal-time bias.

Objective  To emulate a randomized trial of statin therapy initiation that is free of selection bias and immortal-time bias.

Design, Setting, and Participants  We used observational data on 17 372 patients with cancer from the Surveillance, Epidemiology, and End Results (SEER)-Medicare database (2007-2009) with complete follow-up until 2011. The SEER-Medicare database links 17 US cancer registries and claims files from Medicare and Medicaid in 12 US states. We included individuals with a new diagnosis of colorectal, breast, prostate, or bladder cancer who had not been prescribed statins for at least 6 months before the cancer diagnosis. Individuals were duplicated, and each replicate was assigned to either the strategy “statin therapy initiation within 6 months after diagnosis” or “no statin therapy initiation.” Replicates were censored when they stopped following their assigned strategy, and the potential selection bias was adjusted for via inverse-probability weighting. Hazard ratios (HRs), cumulative incidences, and risk differences were calculated for all-cause mortality and cancer-specific mortality. We then compared our estimates with those obtained using the same analytic approaches used in previous observational studies.

Exposures  Statin therapy initiation within 6 months after cancer diagnosis.

Main Outcomes and Measures  Cancer-specific and all-cause mortality using SEER-Medicare data and data from previous studies.

Results  Of the 17 372 patients whose data were analyzed, 8440 (49%) were men, and 8932 (51%) were women (mean [SD] age, 76.4 [7.4] years; range, 66-115 years). The adjusted HR (95% CI) comparing statin therapy initiation vs no initiation was 1.00 (0.88-1.15) for cancer-specific mortality and 1.07 (0.93-1.21) for overall mortality. Cumulative incidence curves for both groups were almost overlapping (the risk difference never exceeded 0.8%). In contrast, the methods used by prior studies resulted in an inverse association between statin use and mortality (pooled hazard ratio 0.69).

Conclusion and Relevance  After using methods that are not susceptible to selection bias from prevalent users and to immortal time bias, we found that initiation of therapy with statins within 6 months after cancer diagnosis did not appear to improve 3-year cancer-specific or overall survival.